ChiCTR1800019501.

Study name	A randomized controlled phase II clinical trial comparing neoadjuvant TP (docetaxel + cisplatin) with TAC (docetaxel + adriamycin + cyclophosphamide) regimen in the treatment of operable triple negative breast cancer
Methods	Accrual: recruiting Accrual target: 212 participants Single‐centre, phase 2 RCT Trial is being conducted in China Blinding: not specified
Participants	Clinical T2‐T4c or T1C with axillary lymph node‐positive Neoadjuvant setting
Interventions	Arm 1: intervention: docetaxel and cisplatin for 6 cycles Arm 2: comparator: docetaxel, doxorubicin and cyclophosphamide for 6 cycles
Outcomes	Primary Pathological complete response rate Secondary Safety Disease‐free survival Rate of breast‐conserving surgery Clinical response rate ypT0ypN0, ypT0/is ypN+, ypT1mic ypN0/+
Starting date	Planned start date: 1 December 2018 Estimated completion date: 31 May 2025
Contact information	Contact: Liu Zhenzhen (liuzhenzhen73@163.com)
Notes	Trial registration link: www.chictr.org.cn/showprojEN.html?proj=31567 Trial sponsor: He'nan Cancer Hospital Funding considerations: self‐funded